Study finds Wegovy by Novo Nordisk reduces heart failure symptoms.
Deprecated: str_getcsv(): the $escape parameter must be provided as its default value will change in /var/www/html/breaking-news/wp-content/plugins/wp-auto-affiliate-links/aal_engine.php on line 361
Novo Nordisk’s Semaglutide Shows Promise in Improving Heart Failure Symptoms
Novo Nordisk’s weight loss and diabetes medication semaglutide, the active ingredient in both Wegovy and Ozempic, has demonstrated its potential to improve symptoms associated with the most common form of heart failure. This adds to the growing list of benefits associated with semaglutide.
A recent study published on Friday examined 529 patients and revealed that a 2.4 milligram dose of semaglutide, which has been approved by the Food and Drug Administration for weight loss, significantly improved patients’ heart failure symptoms. On a 100 point scale, the improvement was nearly 17 points, almost 8 points higher than those who received a placebo.
Furthermore, patients on the high dose of semaglutide experienced a remarkable 13.3% reduction in body weight and demonstrated an improvement in their walking distance by over 20 meters in just six minutes.
This study, partially funded by Novo Nordisk, adds to the mounting evidence suggesting that semaglutide may offer various health benefits. In fact, a separate study conducted earlier this month found that Wegovy, another medication containing semaglutide, has the potential to prevent 1.5 million cardiovascular events, such as heart attacks and strokes, in the United States over the span of 10 years. Additionally, an independent study released on Aug. 8 revealed that Wegovy reduced adverse cardiovascular events by 20% in patients worldwide.
These positive developments have had a significant impact on Novo Nordisk’s stock prices, which increased by nearly 30 points to $189.17 per share on Aug. 8. This week, the stock reached its highest price of $192 per share.
Legal Challenges and Patient Safety
Novo Nordisk and its American competitor Eli Lilly, the manufacturer of the diabetes drug Mounjaro, are currently facing lawsuits regarding possible gastrointestinal complications associated with their diabetes medications. Both companies have emphasized their commitment to prioritizing patient safety.
To learn more about this topic, click here to read more from the Washington Examiner.
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
*As an Amazon Associate I earn from qualifying purchases
